spacer
home > epc > spring 2019 > future-proofing the supply chain
PUBLICATIONS
European Pharmaceutical Contractor

Future-Proofing the Supply Chain

With the regulatory landscape between countries continuing to change and the uncertainty surrounding the changes that Brexit will bring to clinical trial regulations across Europe, it is becoming increasingly important to prepare for changes that might hit the clinical trial supply chain.

With the recent expansion of the clinical trial industry as a result of growing drug innovation and targeted therapies, efforts to tackle ineffectiveness and safety concerns are high on the agenda. From changing import and export regulations to temperature deviation, many challenges will affect the clinical trial supply chain. Planning for these uncertainties, especially in light of prevalent disruptive technologies, now requires more attention than ever.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simon Jones is the Vice President of Global Products for PRISYM ID, responsible for managing the end-to-end lifecycle of the company product portfolio. He has 20 years of experience in delivering product strategies and product positioning which address market opportunities effectively. Simon is a subject expert in clinical trials labelling, researching this market and discussing industry challenges with PRISYM ID customers and keeping them up-to-date on market trends, regulatory changes, and technology alternatives.
spacer
Simon Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement